- MediWound (NASDAQ:MDWD) completes the enrollment of 73 patients in its Phase 2 clinical trial evaluating EscharEx for the treatment of chronic and other hard-to-heal wounds. Top-line results are expected by year end. The estimated study completion date is June 2016.
- The primary endpoint is the incidence of complete non-viable tissue removal (debridement). Secondary endpoints include wound bed preparation and the rate of wound closure.
- EscharEx is a biopharmaceutical for the debridement of eschar (dead tissue).